Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of Etrumadenant in Healthy Adults
NCT05277012Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etrumadenant in solid tumor (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From 0 to Last Observed Non-zero Concentration and 4 more. Started Feb 2022; status: completed.
02
Drugs
etrumadenant
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05277012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277012.